ABUS · Arbutus Biopharma Corp
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-08 | Beardsley Robert A |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. The option is fully vested and exercisable as of the date of the grant. |
Stock Option (Right to Buy)
|
78,800 |
| 2026-06-08 | Sawhney Roger |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. The option is fully vested and exercisable as of the date of the grant. |
Stock Option (Right to Buy)
|
78,800 |
| 2026-02-02 | Androski Lindsay |
Director |
Award↑
Filing footnotes — Common Shares (Direct)
Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. |
Common Shares
|
28,000 |
| 2026-02-02 | Nguyen Tuan |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
188,400 |
| 2026-02-02 | Nguyen Tuan |
Chief Financial Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. |
Common Shares
|
73,500 |
| 2026-02-02 | Androski Lindsay |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
71,700 |
| 2025-08-04 | Sawhney Roger |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2025-08-04 | Sawhney Roger |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd, and 3rd anniversaries of the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
157,600 |
| 2025-03-31 | Nguyen Tuan |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a four-year period, with 25% of the total shares subject to the option vesting on the 1st anniversary of the grant date and the remaining 75% vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
750,000 |
| 2025-03-31 | Nguyen Tuan |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a four-year period, with 25% of the total shares subject to the option vesting on the 1st anniversary of the grant date and the remaining 75% vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
750,000 |
| 2025-03-28 | Nguyen Tuan |
Chief Financial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2025-03-18 | Androski Lindsay |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a four-year period, with 25% of the total shares subject to the option vesting on the 1st anniversary of the grant date and the remaining 75% vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
310,422 |
| 2025-03-18 | Hasija Anuj |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd, and 3rd anniversaries of the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
157,600 |
| 2025-03-18 | Beardsley Robert A |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd, and 3rd anniversaries of the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
157,600 |
| 2025-02-24 | Androski Lindsay |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2025-02-24 | Hasija Anuj |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2025-02-24 | Bishop Joseph E |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2025-02-24 | Beardsley Robert A |
Chief Operating Officer |
Other↑
|
No Securities Owned
|
0 |
| 2025-02-14 | HASTINGS DAVID C |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
365,800 |
| 2025-02-14 | Sims Karen |
Chief Medical Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. |
Common Shares
|
49,300 |
| 2025-02-14 | Sims Karen |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
200,300 |
| 2025-02-14 | Naftzger J. Christopher |
General Counsel and CCO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
220,300 |
| 2025-02-14 | McElhaugh Michael J. |
Director, Interim President & CEO |
Award↑
Filing footnotes — Common Shares (Direct)
Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. |
Common Shares
|
177,000 |
| 2025-02-14 | HASTINGS DAVID C |
Chief Financial Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. |
Common Shares
|
90,100 |
| 2025-02-14 | Naftzger J. Christopher |
General Counsel and CCO |
Award↑
Filing footnotes — Common Shares (Direct)
Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. |
Common Shares
|
54,300 |
| 2025-02-14 | McElhaugh Michael J. |
Director, Interim President & CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
718,800 |
| 2025-02-04 | Naftzger J. Christopher |
General Counsel and CCO |
Sell↓
Filing footnotes — Common Shares (Direct)
Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on July 11, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of previous grants of restricted stock units. Includes 1,214 and 1,263 shares acquired under the Arbutus Biopharma Corporation 2020 Employee Stock Purchase Plan on February 29, 2024 and August 30, 2024, respectively. |
Common Shares
|
11,333 |
| 2025-02-04 | McElhaugh Michael J. |
Director, Interim President & CEO |
Sell↓
Filing footnotes — Common Shares (Direct)
Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 3, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of previous grants of restricted stock units. |
Common Shares
|
23,790 |
| 2025-02-04 | HASTINGS DAVID C |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Shares (Direct)
Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 6, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of previous grants of restricted stock units. |
Common Shares
|
22,183 |
| 2025-02-04 | Sims Karen |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Shares (Direct)
Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 9, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of previous grants of restricted stock units. |
Common Shares
|
19,348 |
| 2024-08-14 | MANCHESTER KEITH S |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Cashless exercise and hold transaction in director stock options due to expire on November 13, 2024, ten years after such options were granted, including the sale of 8,846 of the underlying shares to pay the exercise price. None of the net 46,069 shares were sold. This is a director stock option grant that is fully vested. |
Stock Option (Right to Buy)
|
54,915 |
| 2024-08-14 | MANCHESTER KEITH S |
Director |
Sell↓
Filing footnotes — Common Shares (Direct)
Cashless exercise and hold transaction in director stock options due to expire on November 13, 2024, ten years after such options were granted, including the sale of 8,846 of the underlying shares to pay the exercise price. None of the net 46,069 shares were sold. |
Common Shares
|
8,846 |
| 2024-08-14 | MANCHESTER KEITH S |
Director |
Convert↑
Filing footnotes — Common Shares (Direct)
Cashless exercise and hold transaction in director stock options due to expire on November 13, 2024, ten years after such options were granted, including the sale of 8,846 of the underlying shares to pay the exercise price. None of the net 46,069 shares were sold. |
Common Shares
|
54,915 |
| 2024-05-23 | HENRIQUES RICHARD C JR |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. The option is fully vested and exercisable as of the date of the grant. |
Stock Option (Right to Buy)
|
67,000 |
| 2024-05-23 | Torti Frank |
President and Vant Chair |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. The option is fully vested and exercisable as of the date of the grant. |
Stock Option (Right to Buy)
|
67,000 |
| 2024-05-23 | MANCHESTER KEITH S |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. The option is fully vested and exercisable as of the date of the grant. |
Stock Option (Right to Buy)
|
67,000 |
| 2024-05-23 | Meyers James R |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. The option is fully vested and exercisable as of the date of the grant. |
Stock Option (Right to Buy)
|
67,000 |
| 2024-05-23 | Rewolinski Melissa |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. The option is fully vested and exercisable as of the date of the grant. |
Stock Option (Right to Buy)
|
67,000 |
| 2024-05-23 | BURGESS DANIEL D |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. The option is fully vested and exercisable as of the date of the grant. |
Stock Option (Right to Buy)
|
67,000 |
| 2024-02-02 | Sofia Michael J. |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Shares (Direct)
Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 5, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of a previous grant of restricted stock units. |
Common Shares
|
9,982 |
| 2024-02-02 | Sims Karen |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Shares (Direct)
Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 9, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of a previous grant of restricted stock units. |
Common Shares
|
4,358 |
| 2024-02-02 | HASTINGS DAVID C |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Shares (Direct)
Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 6, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of a previous grant of restricted stock units. |
Common Shares
|
9,593 |
| 2024-02-02 | McElhaugh Michael J. |
Director, Interim President & CEO |
Sell↓
Filing footnotes — Common Shares (Direct)
Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 3, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of a previous grant of restricted stock units. |
Common Shares
|
10,164 |
| 2024-02-01 | Naftzger J. Christopher |
General Counsel and CCO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
380,500 |
| 2024-02-01 | Sofia Michael J. |
Chief Scientific Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. |
Common Shares
|
109,500 |
| 2024-02-01 | Sims Karen |
Chief Medical Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. |
Common Shares
|
101,000 |
| 2024-02-01 | HASTINGS DAVID C |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
450,000 |
| 2024-02-01 | Naftzger J. Christopher |
General Counsel and CCO |
Award↑
Filing footnotes — Common Shares (Direct)
Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. |
Common Shares
|
95,100 |
| 2024-02-01 | McElhaugh Michael J. |
Director, Interim President & CEO |
Award↑
Filing footnotes — Common Shares (Direct)
Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. |
Common Shares
|
123,800 |
| 2024-02-01 | Sofia Michael J. |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
437,800 |